Ann Rheum Dis: Long-term efficacy and safety of caratmonosine in patients with familial Mediterranean fever resistant to autumn daffodils
-
Last Update: 2020-07-13
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The study was designed to assess the long-term efficacy and safety of cluster study Phase 4 (41 weeks to 113 weeks) in the use of kanamonotox to treat familial Mediterranean fever patients (crFMF) with kanamonotox resistance to autumn daffodilsfor 72 weeks, patients receive open-labeled kanazumatherapy of 150 or 300 mg every 4 or 8 weeksAssess disease activity every 8 weeks using physician-based overall assessment of disease activity (PGA), number of seizures, and measurement of C-reactive protein (CRP) and serum amyloid amyloid A (SAA) concentrationsThe safety is studied by identifying and classifying observed adverse events (AEs)Safety and efficacy were analyzed for patients in two subgroups with cumulative doses less than 2700 mg or more than 2700 mgof the 61 patients who started the CLUSTER study, 60 entered stage 4, while 57 completed the studyWithin 72 weeks, 35/60 patients (58.3%) did not experience seizures, while 23/60 patients (38.3%) had 1 seizure, compared with 17.5 per year at baselineThe PGA rating showed that most patients were inactive throughout the studyThe median concentration of CRP is always below 10mg/L, while the median concentration of SAA is still higher than normal (10mg/L), but below the threshold of 30mg/LNo new or unexpected AEs were reportedcrFMF patients with cardazumab therapy for 72 weeks, the incidence of acute onset was very low, and clinical disease activity control was goodNo new security concerns were reported
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
